{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T23:35:51Z","timestamp":1783726551119,"version":"3.55.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s11096-024-01800-3","type":"journal-article","created":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T13:02:15Z","timestamp":1727787735000},"page":"1427-1435","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Cost-effectiveness analysis of selpercatinib versus chemotherapy and pembrolizumab in the first-line treatment of rearranged during transfection fusion\u2013positive non-small cell lung cancer in the United States"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2602-3959","authenticated-orcid":false,"given":"Hongbin","family":"Yi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7414-4674","authenticated-orcid":false,"given":"Yingdan","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2876-7920","authenticated-orcid":false,"given":"Fenghao","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2443-1203","authenticated-orcid":false,"given":"Xiaoxia","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5975-3574","authenticated-orcid":false,"given":"Sheng","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,1]]},"reference":[{"issue":"9","key":"1800_CR1","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/s41571-023-00798-3","volume":"20","author":"A Leiter","year":"2023","unstructured":"Leiter A, Veluswamy RR, Wisnivesky JP. The global burden of lung cancer: current status and future trends. Nat Rev Clin Oncol. 2023;20(9):624\u201339. https:\/\/doi.org\/10.1038\/s41571-023-00798-3.","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"1800_CR2","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1001\/jamaoncol.2018.2706","volume":"4","author":"C Fitzmaurice","year":"2018","unstructured":"Fitzmaurice C, Akinyemiju TF, Al LF, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: A systematic analysis for the global burden of disease study. JAMA Oncol. 2018;4(11):1553\u201368. https:\/\/doi.org\/10.1001\/jamaoncol.2018.2706.","journal-title":"JAMA Oncol"},{"issue":"1","key":"1800_CR3","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jtho.2020.10.127","volume":"16","author":"J Sands","year":"2021","unstructured":"Sands J, Tammem\u00e4gi MC, Couraud S, et al. Lung screening benefits and challenges: a review of the data and outline for implementation. J Thorac Oncol. 2021;16(1):37\u201353. https:\/\/doi.org\/10.1016\/j.jtho.2020.10.127.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"1800_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ccm.2019.10.001","volume":"41","author":"BC Bade","year":"2020","unstructured":"Bade BC, Dela CC. Lung cancer 2020: epidemiology, etiology, and prevention. Clin Chest Med. 2020;41(1):1\u201324. https:\/\/doi.org\/10.1016\/j.ccm.2019.10.001.","journal-title":"Clin Chest Med"},{"issue":"2","key":"1800_CR5","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.bbcan.2015.08.002","volume":"1856","author":"H Lemjabbar-Alaoui","year":"2015","unstructured":"Lemjabbar-Alaoui H, Hassan OU, Yang YW, et al. Lung cancer: biology and treatment options. Biochim Biophys Acta. 2015;1856(2):189\u2013210. https:\/\/doi.org\/10.1016\/j.bbcan.2015.08.002.","journal-title":"Biochim Biophys Acta"},{"issue":"6","key":"1800_CR6","doi-asserted-by":"publisher","first-page":"4346","DOI":"10.1021\/acs.jmedchem.3c02319","volume":"67","author":"ZX Wang","year":"2024","unstructured":"Wang ZX, Li QQ, Cai J, et al. Unraveling the promise of RET inhibitors in precision cancer therapy by targeting RET mutations. J Med Chem. 2024;67(6):4346\u201375. https:\/\/doi.org\/10.1021\/acs.jmedchem.3c02319.","journal-title":"J Med Chem"},{"issue":"9","key":"1800_CR7","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1056\/NEJMoa2005653","volume":"383","author":"A Drilon","year":"2020","unstructured":"Drilon A, Oxnard GR, Tan D, et al. Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer. New Engl J Med. 2020;383(9):813\u201324. https:\/\/doi.org\/10.1056\/NEJMoa2005653.","journal-title":"New Engl J Med"},{"issue":"9","key":"1800_CR8","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1056\/NEJMoa2005651","volume":"383","author":"LJ Wirth","year":"2020","unstructured":"Wirth LJ, Sherman E, Robinson B, et al. Efficacy of selpercatinib in RET-altered thyroid cancers. New Engl J Med. 2020;383(9):825\u201335. https:\/\/doi.org\/10.1056\/NEJMoa2005651.","journal-title":"New Engl J Med"},{"issue":"10","key":"1800_CR9","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/S1470-2045(22)00541-1","volume":"23","author":"V Subbiah","year":"2022","unstructured":"Subbiah V, Wolf J, Konda B, et al. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1\/2, open-label, basket trial. Lancet Oncol. 2022;23(10):1261\u201373. https:\/\/doi.org\/10.1016\/S1470-2045(22)00541-1.","journal-title":"Lancet Oncol"},{"issue":"20","key":"1800_CR10","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.1002\/cncr.34897","volume":"129","author":"Q Zhou","year":"2023","unstructured":"Zhou Q, Zhao J, Chang J, et al. Efficacy and safety of pralsetinib in patients with advanced RET fusion-positive non-small cell lung cancer. Cancer-Am Cancer Soc. 2023;129(20):3239\u201351. https:\/\/doi.org\/10.1002\/cncr.34897.","journal-title":"Cancer-Am Cancer Soc"},{"issue":"7","key":"1800_CR11","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/S1470-2045(21)00247-3","volume":"22","author":"JF Gainor","year":"2021","unstructured":"Gainor JF, Curigliano G, Kim DW, et al. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1\/2 study. Lancet Oncol. 2021;22(7):959\u201369. https:\/\/doi.org\/10.1016\/S1470-2045(21)00247-3.","journal-title":"Lancet Oncol"},{"issue":"20","key":"1800_CR12","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1056\/NEJMoa2309457","volume":"389","author":"C Zhou","year":"2023","unstructured":"Zhou C, Solomon B, Loong HH, et al. First-line selpercatinib or chemotherapy and pembrolizumab in RET fusion-positive NSCLC. New Engl J Med. 2023;389(20):1839\u201350. https:\/\/doi.org\/10.1056\/NEJMoa2309457.","journal-title":"New Engl J Med"},{"issue":"3","key":"1800_CR13","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1001\/jamaoncol.2018.5449","volume":"5","author":"SD Criss","year":"2019","unstructured":"Criss SD, Mooradian MJ, Sheehan DF, et al. Cost-effectiveness and budgetary consequence analysis of durvalumab consolidation therapy vs no consolidation therapy after chemoradiotherapy in stage III non-small cell lung cancer in the context of the US health care system. JAMA Oncol. 2019;5(3):358\u201365. https:\/\/doi.org\/10.1001\/jamaoncol.2018.5449.","journal-title":"JAMA Oncol"},{"issue":"2","key":"1800_CR14","doi-asserted-by":"publisher","first-page":"153","DOI":"10.6004\/jnccn.2020.7621","volume":"19","author":"R Mehra","year":"2021","unstructured":"Mehra R, Yong C, Seal B, et al. Cost-effectiveness of durvalumab after chemoradiotherapy in unresectable stage III NSCLC: a US healthcare perspective. J Natl Compr Canc Ne. 2021;19(2):153\u201362. https:\/\/doi.org\/10.6004\/jnccn.2020.7621.","journal-title":"J Natl Compr Canc Ne"},{"key":"1800_CR15","doi-asserted-by":"publisher","first-page":"803626","DOI":"10.3389\/fphar.2021.803626","volume":"12","author":"Q Liu","year":"2021","unstructured":"Liu Q, Zhou Z, Luo X, et al. Cost-effectiveness of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy in metastatic non-squamous and squamous NSCLC patients With PD-L1 expression \u2265 50. Front Pharmacol. 2021;12:803626. https:\/\/doi.org\/10.3389\/fphar.2021.803626.","journal-title":"Front Pharmacol"},{"issue":"8","key":"1800_CR16","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.37765\/ajmc.2021.88726","volume":"27","author":"MA Chaudhary","year":"2021","unstructured":"Chaudhary MA, Lubinga SJ, Smare C, et al. Cost-effectiveness of nivolumab in patients with NSCLC in the United States. Am J Manag Care. 2021;27(8):e254\u201360. https:\/\/doi.org\/10.37765\/ajmc.2021.88726.","journal-title":"Am J Manag Care"},{"key":"1800_CR17","doi-asserted-by":"publisher","first-page":"107171","DOI":"10.1016\/j.lungcan.2023.03.007","volume":"179","author":"CY Yip","year":"2023","unstructured":"Yip CY, Greystoke A, Abogunrin S, et al. Cost-effectiveness analysis of adjuvant atezolizumab in stage II-IIIA non-small cell lung cancer expressing \u2265\u200950% PD-L1: a United Kingdom health care perspective. Lung Cancer. 2023;179:107171. https:\/\/doi.org\/10.1016\/j.lungcan.2023.03.007.","journal-title":"Lung Cancer"},{"key":"1800_CR18","doi-asserted-by":"publisher","first-page":"e67975","DOI":"10.1136\/bmj-2021-067975","volume":"376","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. BMJ-Br Med J. 2022;376:e67975. https:\/\/doi.org\/10.1136\/bmj-2021-067975.","journal-title":"BMJ-Br Med J"},{"issue":"9","key":"1800_CR19","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1056\/NEJMp1405158","volume":"371","author":"PJ Neumann","year":"2014","unstructured":"Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness\u2014the curious resilience of the $50,000-per-QALY threshold. New Engl J Med. 2014;371(9):796\u20137. https:\/\/doi.org\/10.1056\/NEJMp1405158.","journal-title":"New Engl J Med"},{"issue":"1","key":"1800_CR20","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1093\/heapol\/czz127","volume":"35","author":"M Haacker","year":"2020","unstructured":"Haacker M, Hallett TB, Atun R. On discount rates for economic evaluations in global health. Health Policy Plan. 2020;35(1):107\u201314. https:\/\/doi.org\/10.1093\/heapol\/czz127.","journal-title":"Health Policy Plan"},{"issue":"9","key":"1800_CR21","doi-asserted-by":"publisher","first-page":"e1911952","DOI":"10.1001\/jamanetworkopen.2019.11952","volume":"2","author":"SD Criss","year":"2019","unstructured":"Criss SD, Mooradian MJ, Watson TR, et al. Cost-effectiveness of atezolizumab combination therapy for first-line treatment of metastatic nonsquamous non-small cell lung cancer in the United States. JAMA Netw Open. 2019;2(9):e1911952. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.11952.","journal-title":"JAMA Netw Open"},{"key":"1800_CR22","unstructured":"WebPlotDigitizer. https:\/\/apps.automeris.io\/wpd\/index.zh_CN.html. Accessed 12 Mar 2024."},{"key":"1800_CR23","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/1471-2288-11-139","volume":"11","author":"MW Hoyle","year":"2011","unstructured":"Hoyle MW, Henley W. Improved curve fits to summary survival data: application to economic evaluation of health technologies. BMC Med Res Methodol. 2011;11:139. https:\/\/doi.org\/10.1186\/1471-2288-11-139.","journal-title":"BMC Med Res Methodol"},{"key":"1800_CR24","unstructured":"Drugs.com. Retevmo Prices. Coupons And Patient Assistance. https:\/\/www.drugs.com\/price-guide\/retevmo. Accessed 12 Mar 2024."},{"key":"1800_CR25","unstructured":"Centers for Medicare & Medicaid Services. ASP Pricing Files. https:\/\/www.cms.gov\/medicare\/payment\/part-b-drugs\/asp-pricing-files. Accessed 12 Mar 2024."},{"key":"1800_CR26","unstructured":"Drugs.com. Folic acid Prices, Coupons and Patient Assistance Programs. https:\/\/www.drugs.com\/price-guide\/folic-acid. Accessed 12 Mar 2024."},{"key":"1800_CR27","unstructured":"Centers for Medicare & Medicaid Services. License for Use of Current Procedural Terminology, Fourth Edition (\"CPT\u00ae\"). https:\/\/www.cms.gov\/license\/ama?file=\/files\/zip\/24CLABQ1.zip. Accessed 12 Mar 2024."},{"issue":"4","key":"1800_CR28","first-page":"203","volume":"9","author":"SP Bilir","year":"2016","unstructured":"Bilir SP, Ma Q, Zhao Z, et al. Economic burden of toxicities associated with treating metastatic melanoma in the United States. Am Health Drug Benefits. 2016;9(4):203\u201313.","journal-title":"Am Health Drug Benefits"},{"issue":"6","key":"1800_CR29","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.annonc.2020.02.016","volume":"31","author":"A Fabi","year":"2020","unstructured":"Fabi A, Bhargava R, Fatigoni S, et al. Cancer-related fatigue: ESMO clinical practice guidelines for diagnosis and treatment. Ann Oncol. 2020;31(6):713\u201323. https:\/\/doi.org\/10.1016\/j.annonc.2020.02.016.","journal-title":"Ann Oncol"},{"issue":"17","key":"1800_CR30","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.2217\/imt-2019-0178","volume":"11","author":"M Huang","year":"2019","unstructured":"Huang M, Lopes GL, Insinga RP, et al. Cost-effectiveness of pembrolizumab versus chemotherapy as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in the USA. Immunotherapy-UK. 2019;11(17):1463\u201378. https:\/\/doi.org\/10.2217\/imt-2019-0178.","journal-title":"Immunotherapy-UK"},{"issue":"10","key":"1800_CR31","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1016\/j.cjca.2023.06.011","volume":"39","author":"RA Davies","year":"2023","unstructured":"Davies RA, Ladouceur VB, Green MS, et al. The 2023 canadian cardiovascular society clinical practice update on management of the patient with a prolonged QT interval. Can J Cardiol. 2023;39(10):1285\u2013301. https:\/\/doi.org\/10.1016\/j.cjca.2023.06.011.","journal-title":"Can J Cardiol"},{"issue":"10","key":"1800_CR32","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1177\/0269216315596505","volume":"29","author":"KE Bremner","year":"2015","unstructured":"Bremner KE, Krahn MD, Warren JL, et al. An international comparison of costs of end-of-life care for advanced lung cancer patients using health administrative data. Palliative Med. 2015;29(10):918\u201328. https:\/\/doi.org\/10.1177\/0269216315596505.","journal-title":"Palliative Med"},{"key":"1800_CR33","unstructured":"Bureau of Labor Statistics. Consumer Price Indexes. http:\/\/www.bls.gov\/cpi\/data.htm. Accessed 12 Mar 2024."},{"issue":"5","key":"1800_CR34","doi-asserted-by":"publisher","first-page":"e195","DOI":"10.1111\/ajco.12477","volume":"13","author":"B Nafees","year":"2017","unstructured":"Nafees B, Lloyd AJ, Dewilde S, et al. Health state utilities in non-small cell lung cancer: an international study. Asia-Pac J Clin Oncol. 2017;13(5):e195\u2013203. https:\/\/doi.org\/10.1111\/ajco.12477.","journal-title":"Asia-Pac J Clin Oncol"},{"issue":"4","key":"1800_CR35","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s40258-023-00807-7","volume":"21","author":"J Naik","year":"2023","unstructured":"Naik J, Beavers N, Nilsson F, et al. Cost-effectiveness of lorlatinib in first-line treatment of adult patients with Anaplastic Lymphoma Kinase (ALK)-positive non-small-cell lung cancer in Sweden. Appl Health Econ Health Policy. 2023;21(4):661\u201372. https:\/\/doi.org\/10.1007\/s40258-023-00807-7.","journal-title":"Appl Health Econ Health Policy"},{"issue":"1","key":"1800_CR36","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s10198-019-01117-3","volume":"21","author":"MS Holleman","year":"2020","unstructured":"Holleman MS, Al MJ, Zaim R, et al. Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations. Eur J Health Econ. 2020;21(1):153\u201364. https:\/\/doi.org\/10.1007\/s10198-019-01117-3.","journal-title":"Eur J Health Econ"},{"issue":"4","key":"1800_CR37","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s40273-023-01247-w","volume":"41","author":"KM Al","year":"2023","unstructured":"Al KM, Armstrong N, Howick J, et al. Pralsetinib for RET fusion-positive advanced non-small-cell lung cancer: an evidence review group perspective of a NICE single technology appraisal. Pharmacoeconomics. 2023;41(4):353\u201361. https:\/\/doi.org\/10.1007\/s40273-023-01247-w.","journal-title":"Pharmacoeconomics"},{"issue":"9","key":"1800_CR38","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.21037\/tlcr-23-469","volume":"12","author":"W Liu","year":"2023","unstructured":"Liu W, Huo G, Li M, et al. First-line versus second-line use of pralsetinib in treatment of rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer: a cost-effectiveness analysis. Transl Lung Cancer Res. 2023;12(9):1949\u201358. https:\/\/doi.org\/10.21037\/tlcr-23-469.","journal-title":"Transl Lung Cancer Res"},{"issue":"3","key":"1800_CR39","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1634\/theoncologist.2018-0150","volume":"24","author":"B Wu","year":"2019","unstructured":"Wu B, Gu X, Zhang Q, et al. Cost-effectiveness of osimertinib in treating newly diagnosed, advanced EGFR-mutation-positive non-small cell lung cancer. Oncologist. 2019;24(3):349\u201357. https:\/\/doi.org\/10.1634\/theoncologist.2018-0150.","journal-title":"Oncologist"},{"issue":"2","key":"1800_CR40","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.jtho.2017.10.012","volume":"13","author":"B Wu","year":"2018","unstructured":"Wu B, Gu X, Zhang Q. Cost-effectiveness of osimertinib for EGFR mutation-positive non-small cell lung cancer after progression following first-line EGFR TKI therapy. J Thorac Oncol. 2018;13(2):184\u201393. https:\/\/doi.org\/10.1016\/j.jtho.2017.10.012.","journal-title":"J Thorac Oncol"},{"issue":"9","key":"1800_CR41","doi-asserted-by":"publisher","first-page":"760","DOI":"10.21037\/atm-20-6992","volume":"9","author":"X Xu","year":"2021","unstructured":"Xu X, Fang N, Li H, et al. Cost-effectiveness analysis of dacomitinib versus gefitinib for the first-line therapy of patients with EGFR mutation-positive non-small-cell lung cancer in the United States and China. Ann Transl Med. 2021;9(9):760. https:\/\/doi.org\/10.21037\/atm-20-6992.","journal-title":"Ann Transl Med"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-024-01800-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-024-01800-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-024-01800-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T02:10:21Z","timestamp":1732068621000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-024-01800-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,1]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["1800"],"URL":"https:\/\/doi.org\/10.1007\/s11096-024-01800-3","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,1]]},"assertion":[{"value":"29 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All of the authors have indicated that they have no conflicts of interest with regard to the content of the article. This manuscript is original and has not been previously published, nor has it been simultaneously submitted to any other journal.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}